215 related articles for article (PubMed ID: 32382265)
1. Interplay of
De Benedittis C; Bellan M; Crevola M; Boin E; Barbaglia MN; Mallela VR; Ravanini P; Ceriani E; Fangazio S; Sainaghi PP; Burlone ME; Minisini R; Pirisi M
Gastroenterol Res Pract; 2020; 2020():4216451. PubMed ID: 32382265
[TBL] [Abstract][Full Text] [Related]
2. Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers.
Stickel F; Lutz P; Buch S; Nischalke HD; Silva I; Rausch V; Fischer J; Weiss KH; Gotthardt D; Rosendahl J; Marot A; Elamly M; Krawczyk M; Casper M; Lammert F; Buckley TWM; McQuillin A; Spengler U; Eyer F; Vogel A; Marhenke S; von Felden J; Wege H; Sharma R; Atkinson S; Franke A; Nehring S; Moser V; Schafmayer C; Spahr L; Lackner C; Stauber RE; Canbay A; Link A; Valenti L; Grove JI; Aithal GP; Marquardt JU; Fateen W; Zopf S; Dufour JF; Trebicka J; Datz C; Deltenre P; Mueller S; Berg T; Hampe J; Morgan MY
Hepatology; 2020 Jul; 72(1):88-102. PubMed ID: 31630428
[TBL] [Abstract][Full Text] [Related]
3. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
[TBL] [Abstract][Full Text] [Related]
4. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease.
Seko Y; Yamaguchi K; Tochiki N; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Umemura A; Moriguchi M; Tanaka S; Mori K; Okanoue T; Itoh Y
Liver Int; 2020 Jul; 40(7):1686-1692. PubMed ID: 32342668
[TBL] [Abstract][Full Text] [Related]
5. Severity of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: Relationship between Nongenetic Factors and PNPLA3/HSD17B13 Polymorphisms.
Bellan M; Colletta C; Barbaglia MN; Salmi L; Clerici R; Mallela VR; Castello LM; Saglietti G; Carnevale Schianca GP; Minisini R; Pirisi M
Diabetes Metab J; 2019 Oct; 43(5):700-710. PubMed ID: 31694082
[TBL] [Abstract][Full Text] [Related]
6. A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.
Yang J; Trépo E; Nahon P; Cao Q; Moreno C; Letouzé E; Imbeaud S; Bayard Q; Gustot T; Deviere J; Bioulac-Sage P; Calderaro J; Ganne-Carrié N; Laurent A; Blanc JF; Guyot E; Sutton A; Ziol M; Zucman-Rossi J; Nault JC
Hepatology; 2019 Jul; 70(1):231-240. PubMed ID: 30908678
[TBL] [Abstract][Full Text] [Related]
7. A Variant in PNPLA3 Associated With Fibrosis Progression but not Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection.
Ali M; Yopp A; Gopal P; Beg MS; Zhu H; Lee W; Singal AG
Clin Gastroenterol Hepatol; 2016 Feb; 14(2):295-300. PubMed ID: 26305067
[TBL] [Abstract][Full Text] [Related]
8. The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD.
Vilar-Gomez E; Pirola CJ; Sookoian S; Wilson LA; Liang T; Chalasani N
Clin Transl Gastroenterol; 2021 Sep; 12(9):e00400. PubMed ID: 34506332
[TBL] [Abstract][Full Text] [Related]
9. HSD17B13 and other liver fat-modulating genes predict development of hepatocellular carcinoma among HCV-positive cirrhotics with and without viral clearance after DAA treatment.
Burlone ME; Bellan M; Barbaglia MN; Mocchetti G; Mallela VR; Minisini R; Rigamonti C; Pirisi M
Clin J Gastroenterol; 2022 Apr; 15(2):301-309. PubMed ID: 35098490
[TBL] [Abstract][Full Text] [Related]
10. Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR.
Semmler G; Binter T; Kozbial K; Schwabl P; Chromy D; Bauer D; Simbrunner B; Müllner-Bucsics T; Scheiner B; Stättermayer A; Pinter M; Steindl-Munda P; Trauner M; Ferenci P; Reiberger T; Mandorfer M
J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33917196
[TBL] [Abstract][Full Text] [Related]
11. The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma.
Innes H; Morgan MY; Hampe J; Stickel F; Buch S
Aliment Pharmacol Ther; 2023 Sep; 58(6):623-631. PubMed ID: 37470344
[TBL] [Abstract][Full Text] [Related]
12. Genetic variant rs72613567 of HSD17B13 gene reduces alcohol-related liver disease risk in Chinese Han population.
Chen H; Zhang Y; Guo T; Yang F; Mao Y; Li L; Liu C; Gao H; Jin Y; Che Y; Li Y; Huang J
Liver Int; 2020 Sep; 40(9):2194-2202. PubMed ID: 33151633
[TBL] [Abstract][Full Text] [Related]
13. PNPLA3 rs738409 G allele carriers with genotype 1b HCV cirrhosis have lower viral load but develop liver failure at younger age.
Senkerikova R; Frankova S; Jirsa M; Kreidlova M; Merta D; Neroldova M; Chmelova K; Spicak J; Sperl J
PLoS One; 2019; 14(9):e0222609. PubMed ID: 31527889
[TBL] [Abstract][Full Text] [Related]
14. Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease.
Liu WY; Eslam M; Zheng KI; Ma HL; Rios RS; Lv MZ; Li G; Tang LJ; Zhu PW; Wang XD; Byrne CD; Targher G; George J; Zheng MH
J Clin Transl Hepatol; 2021 Apr; 9(2):194-202. PubMed ID: 34007801
[TBL] [Abstract][Full Text] [Related]
15. PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence.
Falleti E; Fabris C; Cmet S; Cussigh A; Bitetto D; Fontanini E; Fornasiere E; Bignulin S; Fumolo E; Bignulin E; Pirisi M; Toniutto P
Liver Int; 2011 Sep; 31(8):1137-43. PubMed ID: 21745286
[TBL] [Abstract][Full Text] [Related]
16. Analysis of genetic factors associated with fatty liver disease-related hepatocellular carcinoma.
Kogiso T; Ogasawara Y; Horiuchi K; Taniai M; Tokushige K
Cancer Med; 2023 Sep; 12(17):17798-17807. PubMed ID: 37644826
[TBL] [Abstract][Full Text] [Related]
17. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
Stickel F; Buch S; Nischalke HD; Weiss KH; Gotthardt D; Fischer J; Rosendahl J; Marot A; Elamly M; Casper M; Lammert F; McQuillin A; Zopf S; Spengler U; Marhenke S; Kirstein MM; Vogel A; Eyer F; von Felden J; Wege H; Buch T; Schafmayer C; Braun F; Deltenre P; Berg T; Morgan MY; Hampe J
Am J Gastroenterol; 2018 Oct; 113(10):1475-1483. PubMed ID: 29535416
[TBL] [Abstract][Full Text] [Related]
18. Role of candidate gene variants in modulating the risk and severity of alcoholic hepatitis.
Beaudoin JJ; Liang T; Tang Q; Banini BA; Shah VH; Sanyal AJ; Chalasani NP; Gawrieh S
Alcohol Clin Exp Res; 2021 Apr; 45(4):709-719. PubMed ID: 33616244
[TBL] [Abstract][Full Text] [Related]
19. High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant.
Gellert-Kristensen H; Nordestgaard BG; Tybjaerg-Hansen A; Stender S
Hepatology; 2020 Jan; 71(1):56-66. PubMed ID: 31155741
[TBL] [Abstract][Full Text] [Related]
20. Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection.
Huang CF; Dai CY; Yeh ML; Huang CI; Tai CM; Hsieh MH; Liang PC; Lin YH; Hsieh MY; Yang HL; Huang JF; Lin ZY; Chen SC; Yu ML; Chuang WL
J Hepatol; 2015 Mar; 62(3):512-8. PubMed ID: 25457210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
